

Editor-in-Chief

Daniel J. George, MD

Section Editors

Sanjiv S. Agarwala, MD

Robert L. Coleman, MD

Andrew J. Armstrong, MD

Craig M. Kessler, MD

Susan O'Brien, MD

Mark J. Ratain, MD

Hope S. Rugo, MD

Edward S. Kim, MD

Rates & Media

2025

Indexed through the National Library
of Medicine (PubMed/MEDLINE),
PubMed Central (PMC), and EMBASE



EDITORIAL ADVISORY BOARD

Editor-in-Chief

Daniel J. George, MD
Duke University Medical Center

Section Editors

Melanoma in Focus

Sanjiv S. Agarwala, MD
St Luke's Cancer Center and Temple University

Prostate Cancer in Focus

Andrew J. Armstrong, MD
Duke University Medical Center

Colorectal Cancer in Focus

Tanios S. Bekaii-Saab, MD
Mayo Clinic, Phoenix

Ovarian Cancer in Focus

Robert L. Coleman, MD
US Oncology Network

Hematology

Craig M. Kessler, MD
Georgetown University Medical School
Lombardi Comprehensive Cancer Center

Lung Cancer in Focus

Edward S. Kim, MD
City of Hope

Hematologic Malignancies

Susan O'Brien, MD
University of California, Irvine

Drug Development

Mark J. Ratain, MD
The University of Chicago

Breast Cancer in Focus

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center

Founding Editor

Bruce D. Cheson, MD
The Center for Cancer and Blood Disorders

aHUS, TTP

Jeffrey C. Laurence, MD
Weill Cornell Medicine
NewYork-Presbyterian Hospital

BREAST CANCER

Howard A. Burris III, MD
The Sarah Cannon Cancer Center

William Gradishar, MD
Northwestern University

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center

Ruth O'Regan, MD
University of Rochester Medical Center

Lee Schwartzberg, MD
University of Nevada

Sara M. Tolaney, MD
Dana-Farber Cancer Institute

COLORECTAL CANCER

Edward Chu, MD
UPMC Hillman Cancer Center
University of Pittsburgh

David H. Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center

John L. Marshall, MD
Georgetown University Hospital

Mohamed E. Salem, MD
Carolinas Medical Center

Leonard Saltz, MD
Memorial Sloan Kettering Cancer Center

ENDOCRINE CANCER

Alexandria Phan, MD
Medical College of Wisconsin

GASTROINTESTINAL CANCER

Farshid Dayyani, MD
University of California, Irvine

GYNECOLOGIC CANCER

Ursula A. Matulonis, MD
Dana-Farber Cancer Center

HEAD AND NECK CANCER

Marshall R. Posner, MD
Mount Sinai Medical Center

KIDNEY CANCER

Robert A. Figlin, MD
Cedars-Sinai Comprehensive Cancer Center

Brian I. Rini, MD
Vanderbilt University Medical Center

LEUKEMIA

Jan A. Burger, MD, PhD
MD Anderson Cancer Center

Richard R. Furman, MD
Weill Cornell Medicine
NewYork-Presbyterian Hospital

Elias Jabbour, MD
MD Anderson Cancer Center

Hagop M. Kantarjian, MD
MD Anderson Cancer Center

Neil E. Kay, MD
Mayo Clinic, Rochester

Jennifer A. Woyach, MD
Ohio State University

LUNG CANCER

Jeffrey Crawford, MD
Duke University Medical Center

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Roy S. Herbst, MD, PhD
Yale Cancer Center

David H. Johnson, MD
Southwestern Medical Center

Corey J. Langer, MD, FACP
University of Pennsylvania

LYMPHOMA

George P. Canellos, MD
Dana-Farber Cancer Institute

Andre Goy, MD
Hackensack University Medical Center

Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center

Brad S. Kahl, MD
Washington University School of Medicine

Craig H. Moskowitz, MD
University of Miami Sylvester Comprehensive Cancer Center

MELANOMA

John M. Kirkwood, MD
UPMC Hillman Cancer Center

MULTIPLE MYELOMA

Kenneth C. Anderson, MD
Dana-Farber Cancer Institute

James R. Berenson, MD
Institute for Myeloma & Bone Cancer Research

Sundar Jagannath, MD
Mount Sinai Medical Center

Ola Landgren, MD
Sylvester Comprehensive Cancer Center

Paul G. Richardson, MD
Dana-Farber Cancer Institute

MYELOPROLIFERATIVE NEOPLASMS

Guillermo Garcia-Manero, MD
MD Anderson Cancer Center

Claire Harrison, MD, FRCP
Guy's and St Thomas' Hospital

John O. Mascarenhas, MD
Mount Sinai Medical Center

Srdan Verstovsek, MD, PhD
MD Anderson Cancer Center

OVARIAN CANCER

Thomas J. Herzog, MD
University of Cincinnati Medical Center

Maurie Markman, MD
Cancer Treatment Centers of America

PANCREATIC CANCER

Margaret Tempero, MD
University of California, San Francisco Comprehensive Cancer Center

PEDIATRIC HEM/ONC

Mitchell S. Cairo, MD
New York Medical College

PROSTATE CANCER

Michael A. Carducci, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

SARCOMAS/GISTS

George D. Demetri, MD
Dana-Farber Cancer Institute

Clinical Advances in

HEMATOLOGY & ONCOLOGY[™]

A Peer-Reviewed Journal

CEO and Copublisher

Steven H. Kurlander

President and Copublisher

Paul H. McDaniel

Editorial Director

Devon Schuyler

Contributing Editor

Barbara Gormise

Art Director

Tim Jeffs

Indexed in PubMed/MEDLINE and EMBASE

Postmaster: Please send address changes (form 3579) to *Clinical Advances in Hematology & Oncology* c/o DMD, 10255 West Higgins Road, Suite 280, Rosemont, IL 60018.

ISSN: 1543-0790 (print), 2996-2447 (online)

Mission

The mission of *Clinical Advances in Hematology & Oncology* (CAH&O) is to contribute to the advancement of these inter-related fields by providing indispensable editorial content to oncologists, hematologist/oncologists, and pure hematologists. CAH&O fulfills the voiced need of practicing physicians for a practical and readable journal containing the most up-to-date clinical information in malignant and nonmalignant hematologic disorders, as well as solid tumor cancers. CAH&O is also dedicated to being the leader in editorial coverage of targeted therapy.

CAH&O's main editorial departments are:

- Thought leader-driven review articles
- Advances columns featuring engaging interviews with experts on current issues in solid tumor oncology, hematologic malignancies, hematologic disorders, drug development
- Counterpoints: Section addressing clinical controversies in hematology/oncology

Editorial Direction

A peer-reviewed journal, CAH&O provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and hematology, both separately and together. Content is directed by the strong input of experts in the field. CAH&O contains several columns providing cutting edge content on current issues in these fast-moving fields, including:

- In Focus: Breast Cancer, Colorectal Cancer, Chronic Lymphocytic Leukemia, Lung Cancer, Prostate Cancer, Gynecologic Cancer, or Melanoma
- Pro/Con: Experts present their views on controversial issues in hematology and oncology
- Clinical Trials Broadcast: Summaries of ongoing, phase III clinical trials in vital therapeutic areas
- Hem/Onc News: Briefs about the latest developments and global meeting coverage
- Clinical Updates: Peer-reviewed updates on landmark therapeutic developments

Circulation

Clinical Advances in Hematology & Oncology circulates to 27,000 hematology & oncology physicians.

Specialty	Circulation
Colon/Rectal Surgery	2,077
Gynecology/Oncology	891
Hematology	1,283
Hematology/Oncology	11,402
Musculo-Skeletal Oncology	152
Medical Oncology	3,542
Pediatric Hematology/Oncology	2,954
Radiation Oncology	2,500
Surgical Oncology	440
Urology	1,700
Total Circulation	26,941
<i>(As of August 2024)</i>	



2025 Print Advertising Rates

Effective Date: January 2025

Agency Commission: 15% of gross on space, color, and position if paid within 30 days.

Earned Rate: Frequency Discounts are earned on the basis of accumulated ad space placed within a 12-month period. All pages of a parent company and its subsidiaries placed in *Clinical Advances in Hematology & Oncology* are combined to determine the earned rate for the publication.

B&W Page Rates	Full Page	2/3 Page	1/2 Page	1/3 Page	1/4 Page
1x	\$4,525	\$3,860	\$3,050	\$2,395	\$1,766
6x	\$4,470	\$3,795	\$2,990	\$2,325	\$1,695
12x	\$4,395	\$3,720	\$2,925	\$2,265	\$1,640
24x	\$4,315	\$3,655	\$2,875	\$2,200	\$1,560
36x	\$4,250	\$3,560	\$2,790	\$2,135	\$1,500
48x	\$4,195	\$3,525	\$2,735	\$2,070	\$1,430
60x	\$4,160	\$3,490	\$2,690	\$2,030	\$1,395
72x	\$4,120	\$3,455	\$2,660	\$1,990	\$1,370
84x	\$4,085	\$3,430	\$2,625	\$1,960	\$1,335
96x	\$4,050	\$3,400	\$2,600	\$1,895	\$1,300
108x	\$4,020	\$3,390	\$2,565	\$1,865	\$1,275
120x	\$3,990	\$3,320	\$2,525	\$1,830	\$1,230

Color Rates *	6-Color	5-Color	4-Color	3-Color	2-Color	Matched PMS	Metallic
	\$3,035	\$2,710	\$2,225	\$2,100	\$995	\$1,050	\$1,380

* In addition to earned B/W rates; apply to each full or fractional page. No bleed charge.

Inserts	2-page (2x b/w page rate), 4-page (4x b/w page rate), 6-page (6x b/w page rate), 8-page (8x b/w page rate) plus \$800 net insert charge.
BRC's	\$1,770
Cover Tips (supplied)	\$28,650 net (Price based on PITA Pocket Tip w/Folded P.I. inside tips supplied by advertiser to our printer.) \$23,900 net (Price based on single-leaf, 2-sided unbranded tip without P.I. supplied by advertiser to our printer.)

Covers and Premium Rates	Position	B/W Rate Plus
	Cover 4 (2-page minimum)	50%
	Cover 2 (2-page minimum)	25%
	Page opposite 1st Table Contents	20%
	Page opposite 2nd Table of Contents	15%
	Page opposite first editorial page	15%

Continuity Discount Program: Advertise your product in all 6 issues in 2025, and receive a 3% discount on each insertion as placed.

Cancellation Policy: 60 days prior for all position contracts and completion of tasks on SOWs.

Premium Position Cancellation Policy: Written notice required at least 60 days prior to issue closing date. Cancellations made within the 60 Days incur a 50% charge on the entire planned ad unit cost.

Cover Tips

The cost to run a supplied branded PITA Pocket Cover Tip to the full circulation of *CAH&O* is \$28,650 net.

The cost to run a supplied Cover Tip, standard size 2-page (single leaf, front and back), to the full circulation of *CAH&O* is \$23,900 net. Please see the next page for production specifications. *CAH&O* can accommodate variations in size and dimension and will be quoted on an individual basis from provided samples.

Bonus Distribution: The most recent issues of *Clinical Advances in Hematology & Oncology* will be made available to all attendees at the following major oncology meetings:

American Society of Clinical Oncology (March/April and May/June Issues)

American Society of Hematology (November & December Issues)

San Antonio Breast Cancer Symposium (December Issue)

2025 Closing Dates

Issuance: 8 issues

Commitment of Space: 1st of the preceding month (ie, January 1st for the January/February issue).

Material Due Date: 15th of the preceding month (ie, January 15th for the January/February issue).

Insert Due Date: 20th of the preceding month (ie, January 20th for the January/February issue).

Ad Sizing (run-a-book ads)

Ad Unit	Trim Size	Bleed	Live Area
2-Page Spread	16 1/4" (width) x 10 7/8" (height)	16 1/2" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
Full Page	8 1/8" (width) x 10 7/8" (height)	8 3/8" x 11 1/8" (Bleed should extend 1/8" beyond trim size on all sides)	Maintain 1/4" safety zone for live content inside trim. Allow an extra 1/8" safety for gutter allowance.
Half Page Horizontal	8 1/8" (width) x 5.0" (height)	Ad can bleed on top and sides only. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim
Half Page Vertical	4.0" (width) x 10 7/8" (height)	Ad can bleed on top, bottom, and either into gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/4 inch for binding.
Quarter Page	4.0" (width) x 5.0" (height)	Ad can bleed on top and gutter or outer edge. (Extend bleed out 1/8" beyond trim size)	Maintain 1/4" safety zone for live content inside trim. Also, if bleeding into gutter, allow an extra 1/4 inch for binding.

Paper Stock

Paper Stock	Body Pages: 45# coated. Covers: 80# coated.
-------------	---

Specifications for Electronic Files

File Format	Press ready, high res PDF only. (All files and fonts must be embedded; do not save PDF with unlinked OPI data) PDF needs to include crop marks and bleed. Make sure PDF is not set to crop document to frame edges.
-------------	--

Images/Color/Resolution

4 Color Scans	Resolution should be 2x the screen ruling (and at least 300 dpi). Color should be CMYK.
---------------	---

Specifications for Printed Inserts **Insert quantity** (includes spoilage allowance): 29,000.

Sizes	2-, 4-, 6-, or 8-page folded supplied inserts. Maximum 8 3/8" and specification.
Insert Trimming	<ul style="list-style-type: none">– The final trim size needs to be 8 3/8" x 11 1/8"– Inserts jog to foot. This means that our printer will trim an additional 1/8" from the top. Keep this in mind in your design.– Live area: The type should be at least 3/8" from gutter grind, 3/8" from head and 1/4" from face and 1/4" from the foot.
Shipping	Preprinted inserts should be shipped directly to the printer at the address below. Please note the journal name and issue date on your shipment. For contracts or insertion orders, please contact the publisher.

Cover Tip Specifications:

Trim Size: 7.75" (width) x 4.0" (height). Extend bleed out 1/8" beyond trim. Paper weight: Use 70 lb. or 80 lb.

Publisher

Steve Kurlander or Paul McDaniel
Millennium Medical Publishing, Inc.
611 Broadway, Suite 605
New York, NY 10012
Tel: 917-656-7994
e-mail: shk@clinicaladvances.com
phm@clinicaladvances.com

Printer

Kodi Collective
13487 South Preston Highway
Lebanon Junction, KY 40150
Attn: Michael Gladden, H&O, Issue Date

*Please indicate counts on the packing slip and on each of the cartons

Please send a sample of all shipped inserts to the publisher at the address provided at left.

Website Banner Ads

2024 Average Stats*


- Average visit duration = 1 minute, 15 seconds
- Average monthly unique visitors = 35,275
- Average monthly visits = 42,856
- Average monthly page views = 50,585
- Average monthly impressions = 74,604
- 18,651 per 25% share of voice (SOV)
- CTR = 0.12%

*Based on average stats Jan.-June 2024, Google Analytics, WordPress, US only

Hematologyandoncology.net is the online home of the monthly journal, *CAH&O—Clinical Advances in Hematology & Oncology*. Access to the Web site is free for recipients of the print edition of *CAH&O*. Hematologyandoncology.net complements the journal's goal to improve the quality of cancer care by addressing oncology practice for all disease stages and presentations.

Ad Sizes Available

- Leaderboard (728 x 90)
- Medium Rectangle (300 x 250)
- Mobile Leaderboard (320 x 50)



Clinical Advances in Hematology & Oncology e-TOCs

e-TOC Average Stats

- Total distribution: over 21,500 hematology and oncology clinicians and professionals
- Average open rate: 20-25%
- Click-to-open rate: 15%
- Delivery Rate: 99.98%

Two E-mails for Every Issue of CAH&O

e-TOC 1 – “Coming This Month” – delivered two weeks before the printed issue mails

- e-TOC links to hematologyandoncology.net
- Contents of current issue
- Highlights of past issues

e-TOC 2 – “In This Issue” – delivered days before the issue reaches the mailbox

- e-TOC links to hematologyandoncology.net
- Contents of current issue
- Highlights of future issues

Distribution

Primary Specialty	Sum of Count
Gynecological Oncology (GO)	878
Hematology/Oncology (HO)	13,090
Medical Oncology (ON)	3,699
Musculoskeletal Oncology (OMO)	196
Pediatric Hematology/Oncology (PHO)	3,316
Surgical Oncology (SO)	417
Grand Total	21,596

Ad Sizes Available

- Leaderboard (728 × 90)
- Medium Rectangle (300 × 250)
- Wide Skyscraper (160 × 600)

Leaderboard (728 × 90)

Clinical Advances in
HEMATOLOGY & ONCOLOGY
A Peer-Reviewed Journal

[Website](#) | [Archives](#) | [Supplements](#) | [Videos](#) | [MMP Home](#)

July 2015

Coming in the July Issue of CAH&O

The Effect of Cancer Treatment on Cognitive Function
Asmita Kulkarni, MD, and Jamie S. Myers, PhD, RN, AOCNS

Immunotherapy or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma?
Geoffrey T. Gloney, MD, and Michael B. Atkins, MD

July Columns

Second-Generation ALK Inhibitors
Hiroyuki Mano, MD, PhD

The Potential Threat to Blood Transfusion Safety of Emerging Infectious Disease Agents
Susan L. Stramer, PhD

Managing Primary Central Nervous System Lymphoma
Tatya Balachor, MD, MPH

Stool DNA Testing: A New, Noninvasive Option for Colorectal Cancer Screening
David A. Ahlquist, MD

Highlights in Breast Cancer From the 2015 American Society of Clinical Oncology Annual Meeting
Commentary by Edith A. Perez, MD

Supplements to CAH&O

Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium

Emerging Data on Multianalyte Algorithm Assays in Breast Cancer: A Clinical Review

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors

New and Emerging Therapeutic Options for Thyroid Carcinoma

New and Emerging Therapeutic Options for the Management of Chemotherapy-Induced Nausea and Vomiting

Managing Risk in Hodgkin Lymphoma

Medium rectangle
(300 x 250)

Highlights From Past Issues

Renal Cell Carcinoma in Patients With a Personal or Family History of Hematologic Malignancies

Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and Developing Novel Therapeutic Strategies

Non-Clear Cell Renal Cell Carcinoma, Part 2: Therapy

MET as a Drug Target

New Therapies for Polycythemia Vera


Imaging Techniques for Hepatocellular Carcinoma

The Future of Kidney Cancer Treatment

Intermittent Dosing in Melanoma

Hem/Onc News

Video of the Week



TAS-102 vs placebo in patients 65 years with mCRC: An age-based analysis of the RECURSE trial

ASCO 2015 - Eric Van Cutsem, MD, PhD, discusses TAS-102 vs placebo in patients over 65 years with metastatic colorectal cancer - an age-based analysis of the RECURSE trial

Phase III RECURSE Trial
 Abstract #3595 - TAS-102 vs placebo - an age-based analysis of the RECURSE trial

Abstract #3564 - TAS-102 vs placebo - Geographic Subgroups

In This Issue

Cognitive Dysfunction
 Melanoma
 ALK Inhibitors
 Blood Transfusion
 CNS Lymphoma
 Colorectal Cancer
 Breast Cancer
 Immunotherapy

Wide skyscraper
(160 × 600)


Stay Connected

Facebook | Twitter

Forward To A Friend

Clinical Considerations in Patients With Myelofibrosis

Watch Now ▶



NICHOLAS J. SARRIS, MD, PhD

ClinTopics®

Leaderboard (728 × 90)

Millennium Medical Publishing, Inc. | info@clinicaladvances.com | www.hematologyandoncology.net
 911 Broadway #310
 New York, NY 10012

If you no longer wish to receive notifications regarding the most current issue of Clinical Advances in Hematology & Oncology, please click here to unsubscribe. Replies to this message are not monitored or answered.

Copyright © 2015. All Rights Reserved

Millennium Medical Publishing, Inc. | 611 Broadway #310 | New York, NY 10012

Online Advertising Rates & Closing Dates

CAH&O e-TOC Sponsorship

- Single sponsor = \$8,000 net
- Partial sponsor = \$6,000 net

Hematologyandoncology.net Advertising Rates

Limited sponsorship program, offered to just four annual sponsors at \$96,000 net per year. Each sponsor will receive approximately 200,000 total yearly impressions. Fully scalable at \$8,000 net/month.

10% discount for print advertising in the same month.

Digital Cancellations

In accordance with the AAAA/IAB Standard Terms and Conditions for Internet Advertising Version 3.0) found at http://www.iab.net/media/file/IAB_4Astsandcs-FINAL.pdf, Advertiser may cancel the I/O as follows:

For Flat-Fee or Fixed Placements:

- With minimum of 30 days prior written notice: no penalty
- With less than 30 days prior written notice: Advertiser is responsible for any contracted media to be served within 30 days

Send all digital material to Paul McDaniel at pjm@clinicaladvances.com

CAH&O e-TOC Closing Dates*

Email Date	Insertion Order Due	Ad Material Due
1/8/2025	12/21/2024	1/3/2025
1/22/2025	1/8/2025	1/16/2025
2/5/2025	1/22/2025	1/27/2025
2/19/2025	2/5/2025	2/10/2025
3/5/2025	2/19/2025	2/24/2025
3/19/2025	3/5/2025	3/12/2025
4/9/2025	3/26/2025	4/2/2025
4/23/2025	4/9/2025	4/16/2025
5/7/2025	4/23/2025	4/30/2025
5/21/2025	5/7/2025	5/14/2025
6/4/2025	5/21/2025	5/28/2025
6/18/2025	6/4/2025	6/11/2025
7/9/2025	6/25/2025	7/2/2025
7/23/2025	7/9/2025	7/16/2025
8/6/2025	7/23/2025	7/30/2025
8/20/2025	8/6/2025	8/13/2025
9/10/2025	8/27/2025	9/4/2025
9/24/2025	9/10/2025	9/17/2025
10/9/2025	9/24/2025	10/2/2025
10/23/2025	10/8/2025	10/15/2025
11/5/2025	10/22/2025	10/29/2025
11/19/2025	11/16/2025	11/12/2025
12/3/2025	11/19/2025	11/28/2025
12/21/2025	12/10/2025	12/17/2025

*Dates are subject to change.

Digital Specifications

Specification	Website	e-TOC
Accepted ad sizes	Leaderboard (728 × 90)	Leaderboard (728 × 90)
	Medium rectangle (300 × 250)	Medium rectangle (300 × 250)
	Mobile leaderboard (320 × 50)	Wide Skyscraper (160 × 600)
Ad expansion available	Yes	N/A
Ad expansion sizes	Leaderboard (728 × 90)	N/A
Ad expansion notes	Ad must require user initiation before expansion. Expanded ad must include clearly visible close controls.	N/A
Ad formats	JPG, GIF, HTML5, third-party served ads	JPG, GIF, animated GIF
Maximum file size	200K	40K
Rich media file size	200K	N/A
Animation time	15 seconds, 3 loops	15 seconds, 3 loops*
Border	All ads with white or partially white background must use a 1-pixel black border	All ads with white or partially white background must use a 1-pixel black border
Third-party click and pixel tracking available?	By Request	By Request
Alternate text required	Yes	Yes
URL	Provide URL for any links	Provide URL for any links

For times when the user's browser does not support creative functionality (i.e. HTML5), provide a standard image file.

*Please ensure that the first frame of the animated GIF makes sense as a static image.

Contact

Advertising: Paul McDaniel
 phm@clinicaladvances.com
 Tel: (917) 656-7994

Send all insertion orders to:
 phm@clinicaladvances.com

Clinical Advances in
HEMATOLOGY & ONCOLOGY™
A Peer-Reviewed Journal

Millennium Medical Publishing, Inc.
 611 Broadway, Suite 605, New York, NY 10012
 Tel: (917) 656-7994 or (914) 720-4485
 hematologyandoncology.net